Poor injection technique or trauma during administration may cause localised discomfort that radiates to nearby joints
Semaglutide injections reduce appetite through GLP-1 receptor activation, with clinical trials showing an average weight loss of 15% body weight over 68 weeks
At the conclusion of the STEP 1 trial, the average weight loss among the 1,961 participants averaged 14.9% of their initial body weight.[2] For example, if a participant started at 260 pounds and lost 14.9% of their body weight, they would have lost 38.7 pounds
It is also important for individuals to have realistic weight loss goals and be committed to making lifestyle changes, such as adopting a healthy diet and engaging in regular physical activity, to achieve long-term weight management success with Semaglutide GLP-1 treatment
Real people, Real Results Join 100,000+ patients transforming their lives with GLP-1 medication Chelsea D